Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis
Sign Up to like & getrecommendations! Published in 2018 at "Rheumatology"
DOI: 10.1093/rheumatology/kex484
Abstract: Objectives To study the determinants of the pharmacokinetics (PK) of rituximab (RTX) in patients with ANCA-associated vasculitis (AAV) and its association with clinical outcomes. Methods This study included data from 89 patients from the RTX… read more here.
Keywords: clinical outcomes; rtx levels; area; pharmacokinetics rituximab ... See more keywords
THU0309 NONLINEAR PHARMACOKINETICS OF RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.4897
Abstract: Background: Rituximab (RTX) was approved in patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Objectives: To describe the pharmacokinetics of rituximab in AAV patients and to explore its sources of variability Methods: Rituximab pharmacokinetics… read more here.
Keywords: vasculitis; anti neutrophil; pharmacokinetics rituximab; neutrophil cytoplasmic ... See more keywords